HIV Infections Clinical Trial
Official title:
Men's Club: Impact of Male Partner Involvement on Initiation and Sustainment of Exclusive Breastfeeding Among Postpartum Women
Verified date | October 2017 |
Source | University of Nevada, Las Vegas |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Breastfeeding remains the optimal mode of feeding for infants younger than six months.
Exclusive Breast Feeding (EBF) among HIV-infected mothers has been shown to be associated
with a sustained and significant reduction in HIV transmission and has the potential to
reduce infant and under-five mortality.
Given the considerable authority among men as decision makers in sub-Saharan African, we may
be witnessing a missed opportunity to engage men in the education, awareness, and
decision-making for EBF. Understanding the role and impact of male partners on this
decision-making process require further examination to inform the development of effective
and sustainable evidence-based interventions to support the initiation and sustainment of
EBF.
Status | Enrolling by invitation |
Enrollment | 200 |
Est. completion date | March 31, 2018 |
Est. primary completion date | March 15, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Cohabiting couples/partners; residing in Benue state, Nigeria identified during iSTAR recruitment (baby showers) Exclusion Criteria: - HIV-infected females who have not disclosed their status to their male partners; male partners who do not own a phone; multiple pregnancy; and any health-related condition that prevents the female partner from breastfeeding. |
Country | Name | City | State |
---|---|---|---|
Nigeria | Catholic Caritas Foundation | Makurdi | Benue |
Lead Sponsor | Collaborator |
---|---|
University of Nevada, Las Vegas | Catholic Caritas Foundation, Nigeria, University Of Nigeria Teaching Hospital |
Nigeria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Initiation of breastfeeding | Provision of mother's breast milk to infants within one hour of birth; participant self-report during face-to-face interview at 6 weeks post-partum | 6 weeks | |
Primary | Sustainment of exclusive breastfeeding | Any/exclusive breastfeeding at 3 months is measured using a structured questionnaire at 3 months postnatal | 3 months | |
Primary | Difference in rates of sustainment of exclusive breastfeeding | Any/exclusive breastfeeding at 6 months is measured using a structured questionnaire at 6 months postnatal | 6 months | |
Secondary | Difference in breastfeeding knowledge | Breastfeeding Knowledge Questionnaire (survey) at prenatal timepoint and 6 weeks postpartum | Baseline and 6 weeks | |
Secondary | Attitudes towards breastfeeding | Iowa Infant Feeding Attitudes Scale (survey) at 6-weeks post delivery | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |